• 1. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 2. An amphoteric reactivity of a mixed-valent bis(μ-oxo)dimanganese(iii,iv) complex acting as an electrophile and a nucleophile?
  Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383
• 3. An atmosphere and light tuned highly diastereoselective synthesis of cyclobuta/penta[b]indoles from aniline-tethered alkylidenecyclopropanes with alkynes?
  Bo Cao,Yin Wei Chem. Commun., 2018,54, 2870-2873
• 4. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977
• 5. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines Piperidinecarboxylic acids
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines Piperidinecarboxylic acids and derivatives Piperidinecarboxylic acids

Comprehensive Overview of tert-butyl 2-hydroxy-5-azaspiro[3.5]nonane-5-carboxylate (CAS No. 1934510-39-0): Properties, Applications, and Industry Insights

The chemical compound tert-butyl 2-hydroxy-5-azaspiro[3.5]nonane-5-carboxylate (CAS No. 1934510-39-0) has garnered significant attention in pharmaceutical and organic synthesis research due to its unique structural features and versatile applications. This spirocyclic compound combines a 5-azaspiro[3.5]nonane core with a tert-butyl carboxylate group, making it a valuable intermediate in drug discovery and fine chemical production. Its hydroxyl functional group further enhances its reactivity, enabling diverse derivatization pathways.

In recent years, the demand for spirocyclic scaffolds like 5-azaspiro[3.5]nonane derivatives has surged, driven by their prominence in bioactive molecules. Researchers frequently search for "spirocyclic compounds in drug design" or "tert-butyl carboxylate applications," reflecting the compound's relevance in modern medicinal chemistry. The 2-hydroxy substitution on the spiro ring system is particularly noteworthy, as it introduces stereochemical complexity often linked to enhanced binding affinity in target proteins.

The synthesis of CAS 1934510-39-0 typically involves multi-step organic transformations, including ring-closing reactions and protective group strategies for the tert-butyl ester. Analytical characterization via NMR spectroscopy and mass spectrometry confirms its high purity, a critical factor for pharmaceutical-grade intermediates. Industry professionals often inquire about "scale-up methods for spirocyclic intermediates" or "stability of tert-butyl esters," highlighting practical considerations in manufacturing.

From a therapeutic perspective, the 5-azaspiro[3.5]nonane motif appears in compounds targeting neurological disorders and metabolic diseases. This connection fuels searches for "spirocyclic amines in CNS drugs" and "carboxylate prodrug strategies." The tert-butyl 2-hydroxy-5-azaspiro[3.5]nonane-5-carboxylate framework offers opportunities for structure-activity relationship (SAR) studies, particularly in modulating solubility and bioavailability.

Environmental and regulatory aspects of 1934510-39-0 are also trending topics, with queries like "green chemistry approaches for spiro compounds" gaining traction. The compound's low ecotoxicity profile and compatibility with catalytic synthetic methods align with sustainable chemistry principles. Furthermore, its crystalline solid form at room temperature simplifies handling and storage—a practical advantage frequently discussed in process chemistry forums.

Emerging applications in peptide mimetics and covalent inhibitor design have expanded the utility of this scaffold. The hydroxyl group serves as a handle for further modifications, enabling the creation of bifunctional linkers or chiral auxiliaries. Such versatility explains the growing patent activity around azaspiro[3.5]nonane derivatives, particularly in kinase inhibitor development.

Analytical challenges associated with tert-butyl 2-hydroxy-5-azaspiro[3.5]nonane-5-carboxylate often center on stereoisomer separation and polymorph characterization. Advanced techniques like chiral HPLC and X-ray crystallography are employed to address these questions, reflecting the compound's structural complexity. These aspects are crucial for quality control in GMP production environments.

The future outlook for CAS 1934510-39-0 remains promising, with potential expansions into bioconjugation chemistry and materials science. Its balanced lipophilicity, conferred by the tert-butyl group, makes it attractive for prodrug development, while the spiro architecture offers geometric constraints valuable in molecular recognition. As synthetic methodologies evolve, this compound class is poised to address unmet needs in targeted therapeutics and beyond.

• 1934835-43-4(Tert-butyl 2-hydroxy-5-azaspiro[3.4]octane-5-carboxylate)
• 929971-93-7(tert-butyl 8-hydroxy-5-azaspiro[3.5]nonane-5-carboxylate)
• 1363381-56-9(tert-butyl 6-hydroxy-1-azaspiro3.3heptane-1-carboxylate)
• 2306269-68-9(tert-butyl 7-hydroxy-4-azaspiro[2.5]octane-4-carboxylate)
• 2755418-50-7(1-Azaspiro[3.3]heptane-1-carboxylic acid, 6-hydroxy-6-methyl-, 1,1-dimethylethyl ester, cis-)
• 870889-86-4(3-endo-Hydroxy-3-exo-methyl-8-azabicyclo[3.2.1]octane-8-carboxylic Acid t-Butyl Ester)
• 1502162-73-3(Tert-butyl 4-hydroxy-2,2-dimethylpiperidine-1-carboxylate)
• 870889-20-6((1R,3R,5S)-tert-Butyl3-hydroxy-3-methyl-8-azabicyclo3.2.1octane-8-carboxylate)
• 1419101-19-1(tert-butyl cis-6-hydroxy-1-azaspiro[3.3]heptane-1-carboxylate)
• 1389264-27-0(tert-butyl trans-6-hydroxy-1-azaspiro[3.3]heptane-1-carboxylate)